Cel-Sci Corporation

CVM Healthcare Biotechnology

In the quarter to June 2026, EPS grew 65.4%, free cash flow fell 2.33% and total debt fell 39.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

1.79 0.05 +2.87%
Market cap
$30.6M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
−1.64
Beneish M
−2.35
Dividend safety
n/a

Cel-Sci Corporation (CVM) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Cel-Sci Corporation (CVM) trades at a EV/Sales of 35.0×. Over the past ten years it has ranged from 18.7× (June 2026) to 1,960× (April 2021); the current reading is higher than 5% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2020 833× 35.47%
FY2019 615× 282.95%
FY2018 161× (6.29%)
FY2016 171× 94.96%
FY2015 87.9× —

Quarterly newest first

Period EV/Sales Change
Sep 2020 833× (8.27%)
Jun 2020 908× 13.53%
Mar 2020 800× (8.39%)
Dec 2019 873× 42.00%
18 more quarters

Against its own ten years

Low 18.7× High 1,960×
Ten-year median 178×
Current reading's percentile 6

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on CVM